More about
Arthritis
News
November 16, 2024
2 min read
Save
Lorecivivint may be the ‘first disease-modifying treatment’ for knee osteoarthritis
WASHINGTON — Lorecivivint is superior to placebo for improving pain, function and structure at 12 months and beyond in patients with knee osteoarthritis, according to data presented at ACR Convergence 2024.
News
October 16, 2024
8 min read
Save
Joint preservation forges ahead amid uncertainty
The CDC has estimated that 58.5 million U.S. adults have arthritis, with the number projected to increase to 78 million by 2040.
News
September 16, 2024
2 min read
Save
Intravenous golimumab shows long-term benefit for juvenile idiopathic arthritis
Intravenous golimumab yielded a durable clinical response through 116 weeks, with a stable safety profile, in polyarticular-course juvenile idiopathic arthritis, according to data published in The Journal of Rheumatology.
Clinical Guidance
Psoriatic Arthritis
Treatment Options
TNF Inhibitor Therapy for Psoriatic Arthritis
Clinical Guidance
Psoriatic Arthritis
Treatment Options
Nonbiologic Therapy for Psoriatic Arthritis
Clinical Guidance
Psoriatic Arthritis
Overview
Epidemiology and Classification of Psoriatic Arthritis
Clinical Guidance
Rheumatoid Arthritis
Treatment Options
Interleukin-1 Inhibition
Clinical Guidance
Rheumatoid Arthritis
Overview
Preclinical Rheumatoid Arthritis
Clinical Guidance
Rheumatoid Arthritis
Overview
Clinical Features
Clinical Guidance
Rheumatoid Arthritis
Overview